Neurohormonal activation in congestive heart failure: Does it normalize after heart transplantation?;Activación neurohormonal en la insuficiencia cardíaca congestiva: ¿Se normaliza después del trasplante cardíaco?

Revista Espanola de Cardiologia

Volumn 57, Issue 8, 2004, Pages 725-731

  Pérez Villa, Félix ^a   Roig, Eulalia ^a   Ferrer, Elena ^a   Cuppoletti, Alfredo ^a   Llancaqueo, Marcelo ^a   Jimenez, Wladimiro ^a   Sanz, Ginés ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Heart failure; Heart transplantation; Neurohormones

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; ENDOTHELIN; FUROSEMIDE; ISOPRENALINE; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROHORMONE; NORADRENALIN; OKT 3; RENIN; SPIRONOLACTONE; TACROLIMUS;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; EDEMA; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HORMONE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MALE; MEASUREMENT; MEDICAL DOCUMENTATION; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 4744375583     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13064823     Document Type: Article

References (33)

1. Vidal B, Roig E, Pérez-Villa F, Orus J, Pérez J, Jiménez V, et al. Valor pronóstico de las citocinas y neurohormonas en la insuficiencia cardíaca grave. Rev Esp Cardiol 2002;55:481-6
2. Jordán AJ, Esteban A, García M, Monmeneu JV, Espinosa D, Reyes F, et al. Valor pronóstico de los niveles séricos del factor de necrosis tumoral alfa en pacientes con insuficiencia cardíaca. Rev Esp Cardiol 2003;56:160-7.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U S Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
6. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
7. The MERIT-HF Investigators. Effect of metoprolol Cr/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
8. Packer M, Coats A, Fowler M, Katus H, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
9. Pitt B, Zannad F, Remme WJ. The effect of spironolactone, on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;4341:709-17.
10. Taylor KM, Morton IJ, Brown JJ, Caves PK. Hypertension and the renin-angiotensin system following open-heart surgery. J Thorac Cardiovasc Surg 1977;74:840-5.
11. Boldt J, Schindler E, Harter K, Gorlach G, Hempelmann G. Influence of intravenous administration of angiotensin-converting enzyme inhibitor enalaprilat on cardiovascular mediators in cardiac surgery patients. Anesth Analg 1995;80:480-5.
12. Roig E, Pérez-Villa F, Morales M, Jimenez W, Orús J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-7.
13. Silke B. Hemodynamic impact of diuretic therapy in chronic heart failure. Cardiology 1994;84(Suppl 2):115-23.
14. Hacer E, Gullestad L, Tollofsrud S, Lundberg J, Hall C, Djoseland O, et al. Effect of bolus injection versus continous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest 1997;57:361-7.
15. Braith RW, Wood CE, Limacher MC, Pollock ML, Lowenthal DT, Phillips MI, et al. Abnormal neuroendocrine responses during exercise in heart transplant recipients. Circulation 1992;86:1453-63.
16. Geny B, Piquard F, Lonsdorfer J, Haberey P. Endothelin and heart transplantation. Cardiovasc Res 1998;39:556-62.
17. Edwards BS, Hunt SA, Fowler MB, Valantine AH, Anderson LM, Lerman A. Effect of cyclosporine, on plasma endothelin levels in humans after cardiac transplantation. Am J Cardiol 1991;67:782-4.
18. Piquard F, Doutreleau S, Richard R, Mettauer B, Charloux A, Geny B, et al. Is increased circulating endothelin associated with increased complication rate after heart transplantation? J Heart Lung Transplant 2002;21:717-8.
19. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, de Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999; 100:287-91.
20. Geny B, Brandenberger G, Lonsdorfer J, Chakfé N, Haberey P, Piquard F. Circulating adrenomedullin is increased after heart transplantation. Cardiovasc Res 1999;41:731-6.
21. Martínez-Dolz L, Almenar L, Arnau MA, Osa A, Rueda J, Vicente JL, et al. Análisis de los factores que pueden influir en la aparición del fallo agudo del corazón trasplantado. Rev Esp Cardiol 2003;56:168-74.
22. Pérez O, Castro P, Díaz-Araya G, Nettle D, Moraga F, Chiong M, et al. Persistencia del estrés oxidativo postrasplante cardíaco: estudio comparativo entre pacientes con trasplante cardíaco y con insuficiencia cardíaca. Rev Esp Cardiol 2003:56:160-7.
23. Herera Garza EH, Herrera Garza JL, Rodríguez González H, Treviño Treviño A, Ibarra Flores M, Torre Amione G. Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardíaca. Rev Esp Cardiol 2002;55:61-6.
24. Braith R, Mills R, Wilcox C, Convertino V, Davis G, Limacher M, et al. Fluid homeostasis after heart transplantation: the role of cardiac denervation. J Heart Lung Transplant 1996; 15:872-80.
25. Braith R, Mills R, Wilcox C, Davis G, Wood C. Breakdown of blood pressure and body fluid homeostasis in heart transplant recipients. J Am Coll Cardiol 1996;27:375-83.
26. Braith RW, Mills RM, Wilcox CS, Mitchell MJ, Hill JA, Wood CE. High dose angiotensin-converting enzyme inhibition prevents fluid volume expansion in heart transplant recipients. J Am Coll Cardiol 2000;36:487-92.
27. Braith R, Mills R, Wilcox C, Davis G, Hill J, Wood C. High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipients. J Am Coll Cardiol 2003;41:426-32.
28. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J 2000;14:271-8.
29. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003;92:322-9.
30. Hollenberg SM, Lloyd WK, Parrillo JE, Scherer M, Burns D, Tamburro P, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001;104:3091-6.
31. Cuppoletti A, Sitges M, Pérez-Villa F, Orus J, Magriña J, Roig E. Impairment in forearm endothelium-dependent vasodilation after heart transplantation. Transplant Proc 2003;35:2011-3.
32. Ritcher M, Skupin M, Grabs R, Schramm D, Ritcher H, Olbrich HG. New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model. J Heart Lung Transplant 2000;19:1047-55.
33. Richter M, Ritcher H, Olbrich H, Mohr F. Two good reasons for an angiotensin-II type 1 receptor blockade with losartan after cardiac transplantation: reduction of incidence and severity of transplant vasculopathy. Transplant International 2003;16:26-32.